Telesis Bio Inc. (TBIO): Gedhene kewajiban jangka dawa

Telesis Bio, Inc. (TBIO) has established a reputable image in synthetic biology through its benchtop gene printers, while its patent-protected software and consumables create a significant barrier to entry for competitors. This price chart illustrating value trends serves as an indicator of long-term debt, which stands at -0.06. The business relies on US-based production of automated systems that are in high demand within the scientific community and the pharmaceutical industry.

Long-term debt reflects the total credit obligations with a maturity exceeding one year. This metric is calculated by aggregating non-current borrowings that are sensitive to quarterly balance sheet changes. The dynamics of the company's long-term liabilities allow for an assessment of the stability of its capital structure. For Telesis Bio, Inc. (TBIO), this tool is critical when planning R&D. Dependence on grants makes debt management a prerequisite for survival during cyclical downturns in demand for DNA synthesizers.